Clinical Trial Update: Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating fully human bispecific CAR T cells targeting CD20 and CD19 in relapsed or refractory B-cell mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Fully human bispecific anti-CD20/anti-CD19 CAR T cells

Snippet

Sponsor: Medical College of Wisconsin | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING